TAG:
pharmacogenomics
Pharmacogenomics is the study of how genes affect a person’s response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person’s genetic makeup. Medical professionals and administrators hope this will save lives while also enhancing the practice of personalized medicine, in which drugs and drug combinations are optimized for each individual’s unique genetic makeup.
Many drugs that are currently available are “one size fits all,” but they don’t work the same way for everyone. Whether used to explain a patient’s response or lack thereof to a treatment, or act as a predictive tool, personalized medicine hopes to achieve better treatment outcomes, greater efficacy, minimization of the occurrence of drug toxicities and adverse drug reactions (ADRs). Adverse drug reactions are a significant cause of hospitalizations and deaths in the United States.
With the knowledge gained from the Human Genome Project, researchers are learning how inherited differences in genes affect the body’s response to medications. These genetic differences will be used to predict whether a medication will be effective for a particular person and to help prevent adverse drug reactions.
The field of pharmacogenomics is still in its infancy. Its use is currently quite limited, but new approaches are under study in clinical trials. In the future, pharmacogenomics will allow the development of tailored drugs to treat a wide range of health problems, including cardiovascular disease, Alzheimer disease, cancer, HIV/AIDS, and asthma.
The term pharmacogenomics is often used interchangeably with pharmacogenetics. Although both terms relate to drug response based on genetic influences, pharmacogenetics focuses on single drug-gene interactions, while pharmacogenomics encompasses a more genome-wide association approach, incorporating genomics and epigenetics while dealing with the effects of multiple genes on drug response.
“April 5, 1999 Intelligence: Late Breaking Lab News”
As consolidation of hospital ownership goes, so goes laboratory consolidation. The big trend driving consolidation of hospital ownership is the formation of integrated healthcare systems (IHS). According to SMG Marketing Group, a Chicago-based healthcare information and marketing com…
Quest to Pay $1.27 Billion To Buy SB’s Lab Division
CEO SUMMARY: Consolidation is the story of the clinical laboratory industry during the 1990s. The decade will close out with the granddaddy laboratory consolidation of them all! When Quest Diagnostics Incorporated completes its acquisition of SmithKline Beecham Clinical Laboratories later…
“September 28, 1998 Intelligence: Late Breaking Lab News”
Just days ago, Bayer AG announced one of the largest drug-discovery alliances ever created. Bayer will pay Millennium Pharmaceuticals, Inc. $465 million. In return, over a six-year period, Millennium will use genomics techniques to identify cures for various diseases…
Genetic Testing Almost Accented In Market Place
CEO SUMMARY: Advances in molecular and genetic science have generated the first generation of diagnostic assays for clinical use. As these assays reach the public, acceptance is not immediate. Obstacles are many: ethical, cultural, clinical, and economic. Oncormed’s experience during th…
Pharmacogenomics Is The Coming Wave
CEO SUMMARY: It may be gloom and doom today in the clinical laboratory industry, but long term prospects for diagnostic testing are brightening. Increased understanding of human genetics drives new discoveries about how and why the same drug affects individuals differently. Biotech compan…
Pathologists, Clin Labs, Pharmacogenomics & PPMs
AT MY AGE, I AM LEARNING THAT PEOPLE TEND TO HOLD ONE OF TWO OPINIONS about me. It seems that I can frequently be considered a doddering old fool who is totally unhip (although I recall an even earlier generation calling it “unhep”). On the other hand, there are those who grant me great respect. …
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.